Press releases | WebDisclosure

Basculer en Français

9559	Companies
188835	Keywords
120583	Articles
100786	Press releases

Home
Press releases

REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 1 year 8 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 1 year 8 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. La société publie ses résultats opérationnels et financiers pour l’exercice clos le 31 décembre 2023, mettant en avant ses avancées dans le développement de traitements pour les maladies liées à l'âge

Résultats Financiers Biophytis Développement Clinique Maladies Liées À L'âge Traitements
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 1 year 8 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 1 year 8 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024

Biophytis Étude Clinique BIO101 Obésité OBA
PRESS RELEASE

published on 04/08/2024 at 23:04, 1 year 8 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 1 year 8 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 1 year 8 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants

Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE

published on 04/08/2024 at 23:01, 1 year 8 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 1 year 8 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE

published on 04/08/2024 at 23:00, 1 year 8 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030

Biophytis Étude Clinique BIO101 Obésité Perte Musculaire

Accesswire

Published on 12/20/2025 at 00:30, 9 hours 4 minutes ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 11 hours 34 minutes ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 15 hours 4 minutes ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 18 hours 54 minutes ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 20 hours 4 minutes ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE

EQS Group

Published on 12/19/2025 at 22:03, 11 hours 31 minutes ago

EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector
Published on 12/19/2025 at 21:40, 11 hours 54 minutes ago

IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries
Published on 12/19/2025 at 20:35, 12 hours 59 minutes ago

Nobu Manchester breaks ground as Robert De Niro visits Manchester with Salboy
Published on 12/19/2025 at 20:15, 13 hours 19 minutes ago

CSDS EU RNS Name Changes (19 December 2025)
Published on 12/19/2025 at 19:56, 13 hours 37 minutes ago

Original-Research: European Lithium Limited (von First Berlin Equity Research GmbH): Buy

Les Echos

Published on 12/19/2025 at 21:57, 11 hours 37 minutes ago

Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 1 day 1 hour ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 1 day 1 hour ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 1 day 2 hours ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 1 day 2 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE